Stents
Successful drug-eluting stents are under investigation in all types of lesions
Published in Drug Week, May 6th, 2005
According to the report from the Netherlands, "In-stent restenosis is the major drawback of percutancous coronary interventions, occurring in 10-40% of the patients. Recently, new stents have emerged which are loaded with anti-inflammatory, anti-migratory, anti-proliferative or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently in-stent restenosis."
B.L. van der Hoeven and colleagues of Leiden University continued, "In [our] review article the results of human clinical studies investigating drug-eluting stents are...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-05-06)
More Articles from Drug Week
- Angina
Phase IIb GENASIS clinical trial receives recommendation to proceed - Cancer Therapy
Personalized melanoma vaccine trial commences - Drug Development
New drug application filed for narcolepsy therapy Nuvigil - Drug Resistance
Targeting senescence pathways reversed drug resistance in cancer - Peripheral Arterial Disease
Drug-eluting stent trial to treat PAD enrolls first patient at Stanford - AIDS Research
Initiating ART in primary SIV may lead to mucosal immune system restoration - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
